Drug intelligence / Profile preview

disodium cromoglycate + isoprenaline sulphate

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules
Administration: Inhalation

Overview

A combination medication consisting of disodium cromoglycate (20 mg) and isoprenaline sulphate (0.1 mg) with lactose, dispensed as a fine powder in capsules for inhalation via a Spinhaler device. This combination was used primarily for the treatment of asthma, with disodium cromoglycate acting as a mast cell stabilizer to prevent the release of inflammatory mediators, while isoprenaline served as a bronchodilator through its action as a non-selective beta-adrenergic receptor agonist.

Brand names: Intal Co.
Other names: Intal compound

Targets

ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on disodium cromoglycate + isoprenaline sulphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on disodium cromoglycate + isoprenaline sulphate.

Explore the full profile